Charlie was given fillers in his face at 16 and has a rash across his face and body that he hasn't been able to get rid of ...

Christopher Sayed, MD, discusses how hidradenitis suppurativa typically presents and looks forward, following the November approval of bimekizumab.

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH – Get Free Report) saw some unusual options trading on Tuesday. Investors acquired 13,196 call options on the stock. This represents an increase of ...

That’s the message from Cathy O’Brien, CEO of Naturopathica, the botanical skincare brand with five “healing centers” across ...

Funding will accelerate the company's anti-amyloid treatment for rare and common forms of dementia.As well as bringing forward a new class of treatment for inflammatory skin diseases.Sanos Group ...

A study found patients treated with interleukin inhibitors did not experience a difference in the rates of major adverse ...

Artax Biopharma, Inc., a clinical-stage biotechnology company focused on transforming the treatment of autoimmune diseases, today announces achievement of clinical validation through its Phase 2a ...

People with the skin condition psoriasis often have invisible inflammation in the small intes­tine with an increased propensity for ‘leaky gut’, according to new study. These changes in the gut could ...

The U.S. Food and Drug Administration has approved a nose spray to help treat depression, Johnson & Johnson announced Tuesday.

Icelandic drug discovery and development company Arctic Therapeutics (ATx) today announced the successful closing of a ?26.5 million oversubscribed Series A financing from a broad syndicate ...

.Semaglutide: Novo Nordisk Semaglutide is a long-acting oral GLP-1 analogue being developed and investigated by Novo Nordisk. The drug is currently being evaluated under Phase III clinical trial for ...

Johnson & Johnson (NYSE:JNJ) reported its third-quarter 2024 earnings, surpassing analysts' expectations with an adjusted earnings per share (EPS) of $2.04, slightly above the forecasted $2.02. The ...